Characteristics | All patients (n = 103) | H3K27me3 HIST1low (n = 28) | H3K27me3 HIST1high (n = 75) | P |
---|---|---|---|---|
Age, years | 0.42 | |||
Median | 61 | 62 | 60 | |
Range | 22–76 | 37–76 | 22–76 | |
Sex, % | 1.0 | |||
Male | 43 | 42.8 | 44 | |
WBC, × 10e9/L | 67 | 87.9 | 55.6 | 0.57 |
Median | 67 | 87.9 | 55.6 | |
Range | 10–352 | 10–352 | 11–230 | |
Complete response, % | 94 | 88.4 | 96.0 | 0.18 |
Allo-HSCT in 1st CR, % | 23 | 32.1 | 20.0 | 0.2 |
FAB classification,% | 1.0 | |||
0–2 | 51.8 | 50.0 | 52.6 | |
4–5 | 48.2 | 50.0 | 47.4 | |
CD34 expressiona | 0.005 | |||
Mean | 15.3 | 35.0 | 10.3 | |
Range | 0–99 | 12–99 | 0–93 | |
Molecular alterations, % | ||||
FLT3ITD | 47.0 | 37.0 | 50.6 | 0.36 |
DNMT3Ab | 50.5 | 57.6 | 43.1 | 0.25 |
FLT3ITD/DNMT3Ab | 23.1 | 23.1 | 23.1 | 1.0 |
IDH2 (R140)b | 21.9 | 7.6 | 27.6 | 0.05 |
IDH1 (R132)b | 12.1 | 15.3 | 10.7 | 0.72 |
CEBPAb | 5.4 | 7.6 | 4.6 | 0.62 |
ASXL1b | 3.2 | 3.8 | 3.1 | 1.0 |